Hematologic Malignancy
Chronic Lymphocytic Leukemia
CI-CAN-00002362BCLL · CLLExplore in graph →
Hematologic265 active trials6 approved drugs46 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002362BCLL · CLLExplore in graph →
Clinical trials
1,256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (239)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04149821 | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 51 | Asana BioSciencesINDUSTRY | 2 | Jun 7, 2023 | clinicaltrials |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | terminated | Phase 1 | 97 | MEI Pharma, Inc.INDUSTRY | 2 | May 9, 2023 | clinicaltrials |
| NCT03919214 | Hypertension Management in Cancer Patients | terminated | N/A | 4 | Duke UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT00558961 | Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients(GL-CLB-001) | terminated | Phase 1 / Phase 2 | 13 | Jewish General HospitalOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT02292225 | Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) | terminated | Phase 1 | 3 | SecuraBioINDUSTRY | 2 | Feb 27, 2023 | clinicaltrials |
| NCT04595851 | Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications | terminated | N/A | 6 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 6 | Hangzhou Zenshine Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT02225275 | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | terminated | Phase 1 / Phase 2 | 78 | TG Therapeutics, Inc.INDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | terminated | Phase 2 | 51 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 21, 2022 | clinicaltrials |
| NCT01241786 | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL(VZCLLPI0146) | terminated | Phase 2 | 5 | Hackensack Meridian HealthOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | terminated | Phase 1 | 10 | TG Therapeutics, Inc.INDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT04155840 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 1 | University of WashingtonOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT04209621 | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | terminated | Phase 2 | 3 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 9, 2022 | clinicaltrials |
| NCT04160195 | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | terminated | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2022 | clinicaltrials |
| NCT00792831 | Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia | terminated | Phase 2 | 3 | ItalfarmacoINDUSTRY | 1 | Jan 27, 2022 | clinicaltrials |
| NCT03153514 | Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation(CLLTX1) | terminated | Phase 2 | 3 | German CLL Study GroupOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT01585688 | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | terminated | Phase 1 / Phase 2 | 13 | Gilead SciencesINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | terminated | Phase 1 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT02928510 | Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma | terminated | — | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | terminated | Phase 1 | 87 | Aptevo TherapeuticsINDUSTRY | 1 | May 20, 2021 | clinicaltrials |
| NCT04342117 | Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL(REAL) | terminated | — | 2 | SecuraBioINDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT03601819 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | terminated | Phase 1 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | terminated | Phase 1 | 20 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02538614 | Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia | terminated | Phase 1 | 2 | Gilead SciencesINDUSTRY | 1 | Nov 25, 2020 | clinicaltrials |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies | terminated | Phase 2 | 326 | Gilead SciencesINDUSTRY | 2 | Nov 19, 2020 | clinicaltrials |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | terminated | Phase 1 / Phase 2 | 39 | Sunesis PharmaceuticalsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | terminated | Phase 2 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant | terminated | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT01003769 | Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 5 | Mayo ClinicOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT01796470 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | terminated | Phase 2 | 66 | Gilead SciencesINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03436771 | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | terminated | — | 4 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | May 4, 2020 | clinicaltrials |
| NCT01629511 | Allogeneic Stem Cell Transplant for CLL | terminated | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT00899431 | Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections | terminated | Phase 1 | 12 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02557516 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL | terminated | Phase 1 / Phase 2 | 22 | Innate PharmaINDUSTRY | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | terminated | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | terminated | Phase 2 | 4 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02784834 | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | terminated | Phase 1 | 2 | Michael ChoiOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | terminated | Phase 2 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT02614508 | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01090414 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study | terminated | Phase 1 / Phase 2 | 202 | Gilead SciencesINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT01539291 | Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) | terminated | Phase 3 | 161 | Gilead SciencesINDUSTRY | 5 | Aug 20, 2019 | clinicaltrials |
| NCT00949988 | A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia(BMS-CA180105) | terminated | Phase 1 / Phase 2 | 3 | University of California, San DiegoOTHER | 1 | Aug 14, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Jun 15, 2023source: clinicaltrials